Huang Chang-Ming, Lu Hui-Shan, Li Ping, Xie Jian-Wei, Lin Bi-Juan, Zhang Xiang-Fu
Department of Oncology, Affiliated Union Hospital, Fujian Medical University, Fuzhou 350001, China.
Zhonghua Wai Ke Za Zhi. 2008 May 1;46(9):681-4.
To analyze the efficacy and influence of D2 radical resection combined with splenectomy in T3 cancer of upper stomach.
From January 1980 to June 2002, 613 patients with T3 cancer of upper stomach received D2 radical resection. Of these cases, 102 underwent simultaneous splenectomy (splenectomy group), while 511 did not (spleen-preserved group). The metastatic rate of lymph nodes in splenic hilum and along the splenic artery (No. 10, No. 11), 5-year survival rates, recurrence rate, the postoperative complication rate and mortality rate were followed up and compared in the two groups.
The metastasis rate of No. 10 was 23.5% for splenectomy group and 14.9% for spleen-preserved group (P < 0.05). No significant difference was found in No. 11 metastasis between the two groups. The 5-year survival rate of splenectomy group was 39.8%, and was 32.3% in spleen-preserved group (P > 0.05). The recurrence rate of splenectomy group was 55.9%, and was 60.3% in spleen-preserved group (P > 0.05). In the splenectomy group, the 5-year survival rates were similar between patients with and without No. 10 metastasis (P > 0.05). The postoperative complication rate and mortality rate of the splenectomy group were 19.6% and 4.9%, and were 13.7% and 3.1% in the spleen-preserved group, respectively; and no significant difference was found between the two groups (P > 0.05).
D2 radical excision combined splenectomy should be recommended for stage T3 cancer of upper stomach when suspected with No. 10, No. 11 lymph nodes metastasis. Simultaneous splenectomy would not increase the postoperative complication rate and mortality rate.
分析D2根治性切除术联合脾切除术治疗胃上部T3期癌的疗效及影响。
1980年1月至2002年6月,613例胃上部T3期癌患者接受D2根治性切除术。其中,102例行同期脾切除术(脾切除组),511例未行脾切除术(保脾组)。随访并比较两组脾门及脾动脉旁淋巴结(第10、11组)转移率、5年生存率、复发率、术后并发症发生率及死亡率。
脾切除组第10组转移率为23.5%,保脾组为14.9%(P<0.05)。两组第11组转移情况差异无统计学意义。脾切除组5年生存率为39.8%,保脾组为32.3%(P>0.05)。脾切除组复发率为55.9%,保脾组为60.3%(P>0.05)。脾切除组中,第10组有转移和无转移患者的5年生存率相似(P>0.05)。脾切除组术后并发症发生率和死亡率分别为19.6%和4.9%,保脾组分别为13.7%和3.1%;两组差异无统计学意义(P>0.05)。
对于怀疑有第10、11组淋巴结转移的胃上部T3期癌,建议行D2根治性切除联合脾切除术。同期脾切除术不会增加术后并发症发生率和死亡率。